(Reuters) – Swiss drugmaker Roche <ROG.S> said on Friday it would buy U.S. cancer drugmaker Ignyta Inc <RXDX.O> for $1.7 billion.
Roche will buy all of Ignyta’s outstanding shares for $27 each, representing a premium of about 74 percent to its closing price on Thursday. [nBwNlYw5a]
Reuters reported earlier this week that Ignyta was in advanced talks to sell itself. [nL1N1OM03A]
(Reporting by Parikshit Mishra in Bengaluru; Editing by Gopakumar Warrier)